Clinical forecasting is now leveraging innovative informatics capabilities for more precise recruitment and endpoint projections during a study’s crucial…


Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis

Shire's new dry-eye approval means it's time for an Allergan showdown

Shire looks for more ADHD mileage with new data on long-acting prospect

With weight-control peers flailing, Shire keeps growing Vyvanse

Rare disease marketers try creative gambits to stand out online

Shire's potential U.K. move puts 270 jobs at risk

Should Allergan and Shire pull off an ADHD deal?

Shire seeks FDA approval for chewable version of ADHD drug Vyvanse

Shire building $400M biologics plant, adding 400 jobs in Ireland

Shire says Treasury rules won't nix deal for US-based Baxalta